Media Advisory

Thursday, September 27, 2007

NIH to Hold Symposium on Cardiovascular Regenerative Medicine


To accelerate the advancement of stem cell biology from bench to bedside for treatment of cardiovascular disease, the National Institutes of Health (NIH) will host the scientific symposium Cardiovascular Regenerative Medicine at the NIH Natcher Conference Center in Bethesda, Maryland. Sessions will cover lessons learned from hematopoiesis, specification and use of embryonic stem cells and adult stem cells, including those derived from bone marrow (hematopoietic, endothelial progenitor cells, and mesenchymal stem cells) and adult cardiac stem cells that naturally reside in the heart; growth factors to stimulate formation of new blood vessels (vascular regeneration) and to repair or regenerate cardiac tissue (cardiac regeneration); and technologies for monitoring cell activity.


Stem cell therapies to repair or regenerate tissue or blood vessels could provide a revolutionary approach to helping patients with cardiovascular disease, including the almost 16 million Americans who live with damaged heart muscle or blood vessels due to a heart attack, chest pain, or blocked arteries.

The goal of the symposium is to stimulate discussion about tissue specification in stem cell biology and cardiovascular development, and to identify areas of opportunity for applying regenerative therapies to cardiovascular disease. Recent discoveries on the mechanisms of action of various types of stem cells, findings from animal models and cell-based clinical trials, and other issues critical to bridging the gap between knowledge and clinical applications will also be addressed.


Monday, October 1 and Tuesday, October 2,2007
8:00 A.M. – 5:30 P.M. (both days)


Prominent researchers and clinical cardiovascular experts from the United States, as well as Australia, Belgium, Canada, Finland, France, Germany, Japan, and the United Kingdom will discuss the emerging science, animal models, and clinical applications of stem cell therapies for cardiovascular disease.

Elizabeth G. Nabel, M.D., Director, National Heart, Lung, and Blood Institute and Organizing Committee Chair Manfred Boehm, M.D., Principal Investigator within the Cardiology Branch of NHLBI's Division of Intramural Research, will provide opening remarks.

Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at:

The Foundation for the National Institutes of Health was established by the United States Congress to support the mission of the National Institutes of Health — improving health through scientific discovery. The Foundation identifies and develops opportunities for innovative public-private partnerships involving industry, academia, and the philanthropic community. A non-profit, 501(c)(3) corporation the Foundation raises private-sector funds for a broad portfolio of unique programs that complement and enhance NIH priorities and activities.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH…Turning Discovery Into Health®